EDUCATION:
Degree-Granting Education:
1991.9-1996.7, Bachelor, Medicine, Tianjin Medical University,
Tianjin, P.R. China.
2000.9-2003.7, Master, Oncology, Tianjin Medical University,
Tianjin, P.R. China.
2003.9-2006.7, M.D., Tianjin Medical University
Tianjin, P.R. China
EXPERIENCE
Academic Appointments:
1997.9-2001.12 Resident Doctor, Department of Medical Oncology,
Tianjin Medical University Cancer Hospital and Institute, Tianjin
2001.12-2009.12 Attending Doctor, Department of Medical Oncology,
Tianjin Medical University Cancer Hospital and Institute, Tianjin
2009.12-2017.12 Associate chief physician, Department of Medical Oncology, Tianjin Medical University Cancer Hospital and Institute, Tianjin
2017.12- Now Chief physician, Department of Medical Oncology,
Tianjin Medical University Cancer Hospital and Institute, Tianjin
COMMITTEE MEMBERSHIPS:
2019.3-now, Vice chairman, Committee of Lymphoma Malignancies, Chinese Anti-cancer Association (CACA);
2018.1-now, Member of the standing committee, Anti-lymphoma Alliance, Chinese Society of Clinical Oncology (CSCO);
2018.12-now, Vice chairman, Committee of Lymphoma Malignancies, Chinese Aging Well Association;
2018.6-now, Vice chairman, Cancer Internal Medicine Branch, China Association for the Promotion of International Exchanges in Health Care
2016-now, Chairman, Committee of Lymphoma Malignancies, Tianjin Anti-cancer Association
2016-now, Chairman, the youth committee, Tianjin Anti-Aging Association
2014-now, Member of the youth committee, Committee of Clinical Cancer Chemotherapy, CACA
2014-now, Member of Committee of Hematological Malignancies, Tianjin Anti-cancer Association
2013-now, Member of Committee of Urologic Neoplasms, Tianjin Anti-cancer Association
2014-now, Member of Committee of Lymphoma Hematological Malignancies, China Elderly Oncology Association
HONORS AND AWARDS:
2003 The Third Prize of Tianjin Technology Progress Award, China
The Basic and Clinical Study of the Improved Effect of Ginsenoside Rg3 for Immune Reconstitution After Autologous Peripheral Blood Stem Cell Transplantation
2005 The Excellent Paper Award of Livzon Fund, China,CSCO
The Clinical Study of the Improved Effect of Ginsenoside Rg3 for Immune Reconstitution After Autologous Peripheral Blood Stem Cell Transplantation
2006 The Second Prize of Tianjin Technology Progress Award, China
The Prospective Study on the Relapse of Patients with Malignant Lymphoma after Autologous Hematopoietic Stem Cell Transplantation.
2013 Young Investigator Award of the 22nd Asia Pacific Cancer Conference (APCC)
2016 The Third Prize of Tianjin Technology Progress Award, China
The clinical application and establishment of malignant lymphoma associated with venous thrombosis risk score model